I'd like to see a $2 million dollar based on the increased distribution and the launch of the advertising campaign towards the end of the quarter, but with the quarter two numbers coming in at $1.2 million, a little less than $2 million may be more realistic.
I've stated this before, I think that the company and the product are gaining traction and are in the early stages of a huge growth phase, a growth phase that I believe will be in full effect by the end of the first quarter next year - based on previous comments by CEO Steve Haley.
Additionally, I think that we may see another distribution deal announced either this week or early next week, again based on previous comments by the CEO where he indicated that there are quite a few deals in the works.
As with all growing companies, the small investor wants to have a position in the stock before the huge growth numbers come out, in my opinion, because by that time you might end up chasing a run.
While I do see a possibility of a late year run taking place, I wouldn't rule out another dip into the mid thirties and I maintain my position that the first half of next year will have CSUH trading very significantly higher than it is now.
Just my opinion.
Disclosure: VFC is long CSUH.
CVM: Shares of Cel Sci continue to trade with volatility, although not so much on Wednesday when shares traded relatively flat for the day and closed down only five percent; not much of a loss when you consider the much larger price swings both up and down over the past few weeks.
I would blame no one for flipping a few 'trading shares' in order to be on house's money with this one - especially if some profit is banked along the way. It's a risky proposition at this point, because recent trading and developments have me believing that news is imminent. If that news is positive, and there's a few fourth quarter developments that could move the CVM stock, you wouldn't want to be on the sidelines when it hits.
That being said, nothing is a sure thing in the market, hence the idea that the small investor needs to protect themselves by flipping a few trading shares here and there to protect their investment.
The news wires will tell the story soon enough, in my opinion, and VFC is a patient kinda guy.
Disclosure: VFC is long CVM.
NRIFF.pk: No news was released on November 4th from Nuvo Research regarding the approval for Pennsaid, Nuvo's lead drug that has been partnered with Covidien for distribution in the United States.
The stock traded up 15% on Wednesday on anticipation of news that never came.
It's been painfully obvious that the FDA is way behind when it comes to approvals and reviews, so investors should be patient and watch the wires and not take any delay as a negative sign, in my opinion.
On the same note, it's also good to keep in mind that nothing is a sure thing in regards to the FDA or the stock market, and if you've purchased shares in the teens or low twenties, it may be wise to take a little bit off the table to realize some profit. Just my opinion, of course, and that is not an indication that I believe that the FDA will deny Pennsaid an approval, I just think it's prudent to take some profit on the way up.
For now, it's a news wire watching game.
Disclosure: VFC is long NRIFF.
1 COMMENTS:
Thanks for all the hard work brother. Which wire services do you watch the closest for FDA approvals?
james, los angeles
Post a Comment